SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-Q’ for 9/30/13 – ‘R14’

On:  Tuesday, 11/12/13, at 8:52am ET   ·   For:  9/30/13   ·   Accession #:  1564590-13-1200   ·   File #:  0-19627

Previous ‘10-Q’:  ‘10-Q’ on 8/9/13 for 6/30/13   ·   Next:  ‘10-Q’ on 5/12/14 for 3/31/14   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/12/13  Biolase, Inc                      10-Q        9/30/13   65:8.2M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    543K 
 2: EX-4        Ex-4.2                                              HTML     65K 
 3: EX-4        Ex-4.3                                              HTML     63K 
 4: EX-10       Ex-10.4                                             HTML     47K 
 5: EX-31       Ex-31.1                                             HTML     27K 
 6: EX-31       Ex-31.2                                             HTML     28K 
 7: EX-32       Ex-32.1                                             HTML     21K 
 8: EX-32       Ex-32.2                                             HTML     22K 
64: R1          Document and Entity Information                     HTML     41K 
45: R2          Consolidated Balance Sheets                         HTML    136K 
42: R3          Consolidated Balance Sheets (Parenthetical)         HTML     48K 
17: R4          Consolidated Statements Of Operations And           HTML    105K 
                Comprehensive Loss                                               
44: R5          Consolidated Statements Of Cash Flows               HTML    144K 
31: R6          Basis of Presentation                               HTML     55K 
57: R7          Recent Accounting Pronouncements                    HTML     30K 
32: R8          Stock-Based Awards and Per Share Information        HTML    222K 
34: R9          Inventory                                           HTML     37K 
18: R10         Property, Plant, and Equipment                      HTML     53K 
33: R11         Intangible Assets and Goodwill                      HTML    101K 
56: R12         Accrued Liabilities and Deferred Revenue            HTML    110K 
52: R13         Lines Of Credit and Other Borrowings                HTML     55K 
43: R14         Commitments and Contingencies                       HTML     42K 
61: R15         Segment Information                                 HTML     56K 
55: R16         Concentrations                                      HTML     28K 
15: R17         Income Taxes                                        HTML     41K 
20: R18         Subsequent Event                                    HTML     22K 
60: R19         Accounting Policies (Policies)                      HTML    114K 
63: R20         Stock-Based Awards and Per Share Information        HTML    192K 
                (Tables)                                                         
65: R21         Inventory (Tables)                                  HTML     34K 
62: R22         Property, Plant, and Equipment (Tables)             HTML     49K 
47: R23         Intangible Assets and Goodwill (Tables)             HTML     93K 
19: R24         Accrued Liabilities and Deferred Revenue (Tables)   HTML    116K 
30: R25         Segment Information (Tables)                        HTML     47K 
23: R26         Basis of Presentation - Additional Information      HTML     67K 
                (Detail)                                                         
22: R27         Classification of Compensation Expense Associated   HTML     29K 
                with Share-Based Payments (Detail)                               
36: R28         Assumptions Used in Estimating Fair Value of Stock  HTML     32K 
                Options Granted (Detail)                                         
46: R29         Summary of Option Activity (Detail)                 HTML     72K 
53: R30         Cash Proceeds Along with Fair Value Disclosures     HTML     39K 
                Related to grants Exercises and Vesting Options                  
                (Detail)                                                         
27: R31         Stock Based Awards and Per Share Information -      HTML    115K 
                Additional Information (Detail)                                  
37: R32         Components of Inventory (Detail)                    HTML     32K 
59: R33         Inventory - Additional Information (Detail)         HTML     25K 
25: R34         Summary of Property, Plant, and Equipment (Detail)  HTML     36K 
50: R35         Property, Plant, and Equipment - Additional         HTML     22K 
                Information (Detail)                                             
51: R36         Intangible Assets Related to Accumulated            HTML     52K 
                Amortization and Goodwill (Detail)                               
38: R37         Intangible Assets and Goodwill - Additional         HTML     24K 
                Information (Detail)                                             
21: R38         Components of Accrued Liabilities (Detail)          HTML     43K 
49: R39         Changes In Initial Product Warranty Accrual and     HTML     38K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
26: R40         Summary of Deferred Revenue (Detail)                HTML     37K 
35: R41         Lines of Credit and Other Borrowings - Additional   HTML    111K 
                Information (Detail)                                             
54: R42         Commitments and Contingencies - Additional          HTML     32K 
                Information (Detail)                                             
29: R43         Summary of Net Revenue by Geographic Location       HTML     24K 
                (Detail)                                                         
48: R44         Segment Information - Additional Information        HTML     30K 
                (Detail)                                                         
41: R45         Concentrations - Additional Information (Detail)    HTML     31K 
24: R46         Income Taxes - Additional Information (Detail)      HTML     57K 
58: R47         Subsequent Event - Additional Information (Detail)  HTML     21K 
40: XML         IDEA XML File -- Filing Summary                      XML     91K 
16: EXCEL       IDEA Workbook of Financial Reports                  XLSX    134K 
39: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.26M 
 9: EX-101.INS  XBRL Instance -- biol-20130930                       XML   1.59M 
11: EX-101.CAL  XBRL Calculations -- biol-20130930_cal               XML    132K 
12: EX-101.DEF  XBRL Definitions -- biol-20130930_def                XML    710K 
13: EX-101.LAB  XBRL Labels -- biol-20130930_lab                     XML    998K 
14: EX-101.PRE  XBRL Presentations -- biol-20130930_pre              XML    800K 
10: EX-101.SCH  XBRL Schema -- biol-20130930                         XSD    161K 
28: ZIP         XBRL Zipped Folder -- 0001564590-13-001200-xbrl      Zip    135K 


‘R14’   —   Commitments and Contingencies


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.8
Commitments and Contingencies
9 Months Ended
Commitments and Contingencies

NOTE 9—COMMITMENTS AND CONTINGENCIES

Leases

The Company leases its corporate headquarters and manufacturing facility in Irvine, California and also leases certain other facilities, office equipment, and automobiles under various operating lease arrangements. Future minimum rental commitments under operating lease agreements with non-cancelable terms greater than one year for the years ending December 31, 2013, 2014, and 2015, is $408,000, $661,000, and $192,000, respectively.

Employee arrangements and other compensation

Certain members of management are entitled to severance benefits payable upon termination following a change in control, which would approximate $716,000 at September 30, 2013. The Company also has agreements with certain employees to pay bonuses based on targeted performance criteria. No amount was required to be accrued at September 30, 2013.

Purchase commitments

The Company generally purchases components and subassemblies for its products from a limited group of third party suppliers through purchase orders. The Company had $12.8 million of purchase commitments as of September 30, 2013, for which the Company has not received the goods or services and which is expected to be purchased within one year. These purchase commitments were made to secure better pricing and to ensure the Company will have the necessary parts to meet anticipated near term demand.

Litigation

The Company discloses material loss contingencies deemed to be reasonably possible and accrues for loss contingencies when, in consultation with its legal advisors, management concludes that a loss is probable and reasonably estimable. The ability to predict the ultimate outcome of such matters involves judgments, estimates, and inherent uncertainties. The actual outcome of such matters could differ materially from management’s estimates.

Class Action Lawsuits

On August 23, 2013 and August 26, 2013, two putative securities class action lawsuits were filed against the Company and certain of its officers and directors in the United States District Court for the Central District of California, one of which seeks unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired the Company’s common stock between January 7, 2013 and August 12, 2013, and the other of which seeks similar remedies on behalf of a putative class of persons who purchased or otherwise acquired the Company's common stock between November 5, 2012 and August 12, 2013. Both complaints allege that the Company and certain of its officers and directors violated the federal securities laws by making allegedly materially false and misleading statements and/or material omissions during the putative class periods. On October 22, 2013, four individual plaintiffs each filed motions to consolidate these actions and to be appointed as lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. Those motions are currently scheduled to be heard on December 13, 2013. No other dates have been set. As of September 30, 2013, the Company has accrued $250,000 for legal costs expected to be incurred in connection with these matters. The Company believes that the claims contained in the lawsuits are without merit and intends to vigorously defend against the claims.

Intellectual Property Litigation

On April 24, 2012, CAO Group, Inc. (“CAO”) filed a lawsuit against the Company in the District of Utah for patent infringement of U.S. Patent No. 7,485,116 regarding BIOLASE’s EZlase dental laser. On September 9, 2012, CAO filed its First Amended Complaint, which added claims for (1) business disparagement/injurious falsehood under common law and (2) unfair competition under 15 U.S.C. Section 1125(a). The additional claims stem from a press release that the Company issued on April 30, 2012, which CAO claims contained false statements that are disparaging to CAO and its diode product. The First Amended Complaint seeks injunctive relief, treble damages, attorneys’ fees, punitive damages, and interest. On November 13, 2012, the Court stayed the lawsuit for 120 days to allow the United States Patent and Trademark Office (“USPTO”) to consider the Company’s request for reexamination of the patent-in-suit. The USPTO granted the request to reexamine the asserted claims of the patent-in-suit and, on February 28, 2013, the Court stayed the lawsuit until the termination of the reexamination proceedings. On April 23, 2013, the USPTO issued an office action rejecting all of the asserted claims over the prior art, and CAO responded to the office action. On August 28, 2013, the USPTO issued an Action Closing Procedure, rejecting all of CAO’s patent claims. CAO has responded to the USPTO’s latest ruling.

The Company filed a patent infringement lawsuit against Fotona dd. (“Fotona”) in Düsseldorf District Court alleging infringement with respect to the Fotona Fidelis dental laser system. Oral proceedings are currently scheduled for spring 2014. Fotona denies liability and seeks the reimbursement of statutory fees from the Company. Together with its response brief, Fotona also filed a nullity action against the patent in dispute, patent number EP 1 560 470. The nullity action is pending at the German Federal Patent Court (the “Patent Court”), Docket No. 1 Ni 58/13 (EP). On September 2, 2013, the Company filed its counterplea in the infringement proceedings and phrased its arguments defending the validity of the patent. These arguments were also the subject of the defense brief to the Patent Court in the parallel nullity action proceedings. On September 9, 2013, the Company filed its response to the Patent Court.

Other Matters

In the normal course of business, the Company is subject to other legal proceedings, lawsuits, and other claims. Although the ultimate aggregate amount of probable monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations or cash flows. However, there can be no assurance with respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially from those projected.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
12/31/1510-K,  SD
12/31/1410-K,  10-K/A,  SD
12/31/1310-K,  10-K/A,  SD
12/13/133
Filed on:11/12/138-K
10/22/13
For Period end:9/30/13
9/9/13
9/2/13
8/28/13CORRESP
8/26/138-K
8/23/13UPLOAD
8/12/13
4/23/13
2/28/13
1/7/138-K
11/13/124
11/5/128-K
9/9/12
4/30/128-K
4/24/128-K
9/15/09
 List all Filings 
Top
Filing Submission 0001564590-13-001200   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 8:35:51.1am ET